(Q39672349)

English

Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression

scientific article published on August 3, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

author name string

Jürgen Sonnemann

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Chithra D. Palani

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20680659

15 June 2024

James F. Beck

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20680659

15 June 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20680659

15 June 2024

publication date

3 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

full work available at URL

https://link.springer.com/content/pdf/10.1007/s10637-010-9510-7.pdf

Portable Document Format

1 reference

10.1007/S10637-010-9510-7

https://api.crossref.org/works/10.1007/S10637-010-9510-7

15 June 2024

https://link.springer.com/article/10.1007/s10637-010-9510-7/fulltext.html

1 reference

10.1007/S10637-010-9510-7

https://api.crossref.org/works/10.1007/S10637-010-9510-7

15 June 2024

http://link.springer.com/content/pdf/10.1007/s10637-010-9510-7

1 reference

10.1007/S10637-010-9510-7

https://api.crossref.org/works/10.1007/S10637-010-9510-7

15 June 2024

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

25-36

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

p53 in health and disease

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Awakening guardian angels: drugging the p53 pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

HDAC inhibitor-based therapies and haematological malignancy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Histone deacetylase inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

HDACi--targets beyond chromatin.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Development of vorinostat: current applications and future perspectives for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Romidepsin for the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Modes of p53 regulation

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Acetylation is indispensable for p53 activation

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Deacetylation of p53 modulates its effect on cell growth and apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Drug combination studies and their synergy quantification using the Chou-Talalay method

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Analyzing real-time PCR data by the comparative C(T) method

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Histone deacetylase inhibitors: molecular mechanisms of action

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Hdmx modulates the outcome of p53 activation in human tumor cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Butyrate Activates the WAF1/Cip1 Gene Promoter through Sp1 Sites in a p53-negative Human Colon Cancer Cell Line

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Inactivation of the p53 pathway in retinoblastoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9510-7

21 January 2018

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20680659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20680659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20680659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20680659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-010-9510-7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39672349&oldid=2203074870"